Research programme: PRIMATIZED anti-CD80 antibodies - IDEC Pharmaceuticals

Drug Profile

Research programme: PRIMATIZED anti-CD80 antibodies - IDEC Pharmaceuticals

Alternative Names: Anti-B7 antibody humanised; Humanised anti-B7 antibody; PRIMATIZED anti-B7 antibodies; PRIMATIZED anti-B7-1 antibodies; PRIMATIZED anti-CD80 antibodies - IDEC

Latest Information Update: 10 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDEC Pharmaceuticals
  • Developer IDEC Pharmaceuticals; Mitsubishi Chemical
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Inflammation

Most Recent Events

  • 13 May 1998 Preclinical development for Psoriasis in Japan (Unknown route)
  • 13 May 1998 Preclinical development for Psoriasis in USA (Unknown route)
  • 29 Oct 1997 Preclinical development for Inflammation in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top